<DOC>
	<DOCNO>NCT02133937</DOCNO>
	<brief_summary>This single-center , randomize open-label , single-dose , parallel group study investigate relative bioavailability high concentration liquid formulation ( HCLF ) versus reference lyophilize formulation ( LyoF ) gantenerumab . Healthy volunteer randomize 1:1 receive single-dose gantenerumab subcutaneous injection .</brief_summary>
	<brief_title>A Study Investigating Bioavailability High Concentration Liquid Formulation Versus Reference Lyophilized Formulation Gantenerumab Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male female subject , 40 70 year age inclusive . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , coagulation , serology urinalysis . Some medical condition allow well control single stable medication A BMI 18.0 30.0 kg/m2 inclusive Use highly effective contraception 6 month study followup visit Agree donate blood blood product transfusion duration study one year dose Suspicion alcohol drug abuse addiction use DSM IV criterion Regular smoker ( &gt; 5 cigarette , &gt; 1 pipeful &gt; 1 cigar per day ) , tobacco user subject nicotine replacement therapy Prior administration gantenerumab Participation investigational drug device study within 60 day dose Donation blood 500 mL within three month dose Pregnancy breastfeed Any abnormal skin condition potentially obscure tattoo , pigmentation lesion area intend subcutaneous injection Any familial history early onset Alzheimer 's disease Claustrophobia , presence pacemaker , aneurysm clip , artificial heart valve , ear implant , foreign metal object eye , skin body would contraindicate MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>